Comparison of cimetidine 800 mg once daily and 400 mg twice daily in acute duodenal ulceration. 1984

L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner

A double blind trial was conducted in seven centres to evaluate the safety and efficacy of cimetidine 800 mg given at night compared with 400 mg given at breakfast and at bedtime. Altogether 197 patients with active duodenal ulcer confirmed by endoscopy entered the study, of whom 187 were eligible for analysis. After four weeks' treatment the ulcer was healed in 76 of 91 patients (84%) receiving the once daily regimen and in 65 of the 96 patients (68%) receiving the twice daily regimen (p less than 0.05). Both dosage regimens were equally effective in reducing ulcer pain and consumption of antacids. Pain relief was considerable within the first two weeks, and most of the patients were free of symptoms by the end of treatment. No patients were withdrawn because of adverse events as these were few and mild, consistent with the proved safety profile of cimetidine. Cimetidine 800 mg given at night is as effective as 400 mg twice daily; the single dose regimen may improve patient compliance, thus facilitating treatment.

UI MeSH Term Description Entries
D008297 Male Males
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000863 Antacids Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. Alkalinizing Agent,Antacid,Alkalinizing Agents,Agent, Alkalinizing,Agents, Alkalinizing

Related Publications

L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1990, The Journal of international medical research,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1985, Current medical research and opinion,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
August 1986, The British journal of clinical practice,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1985, G.E.N,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1997, Chemotherapy,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1986, Scandinavian journal of gastroenterology. Supplement,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1986, Scandinavian journal of gastroenterology. Supplement,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
August 2013, Therapeutic drug monitoring,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
January 1988, Drugs,
L Capurso, and P R Dal Monte, and F Mazzeo, and G Menardo, and A Morettini, and A Saggioro, and G Tafner
July 1981, Medizinische Klinik,
Copied contents to your clipboard!